ImageneBio, Inc. (IMA)
Healthcare
Biotechnology
5.60 $
+1.8%
vs. previous close
Closing price · As of: 3. Aug 2026
ImageneBio, Inc. (IMA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -48 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| -12 | 48 | -38 | -60 | -74 | -80 | -46 | -48 | |
| 0.4 | 0.2 | 0.3 | 0.5 | 0.8 | 1.0 | 0.5 | 0.3 | |
| 0.3 | 1.2 | 1.8 | 5.2 | 7.5 | 7.6 | 5.3 | 15 | |
| 0.1 | 63 | -7.8 | -33 | -15 | -22 | -4.0 | -19 | |
| 0.3 | 0.3 | 0.8 | 1.8 | 1.4 | 0.4 | 0.0 | 0.0 | |
| 11 | -0.3 | 2.9 | -1.8 | -99 | 64 | -35 | -5.8 | |
| – | – | -0.1 | – | – | -0.7 | – | – | |
| – | – | – | – | – | 0.0 | 7.5 | 15 | |
| – | 16 | 116 | 132 | 1.1 | 76 | 6.9 | 135 | |
| -0.6 | 64 | 81 | 70 | -172 | 60 | -81 | 82 | |
| -12 | 48 | -39 | -62 | -76 | -80 | -46 | -48 |
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.